Clinical Research Directory

Inclusion Criteria: Prepubertal HSCT Group - Pediatric Oncology Patients * HSCT performed for pediatric oncology between January 2005 and December 2020; * Pubertal development not yet initiated at the time of HSCT (testicular volume \< 4 ml bilaterally, uterine volume \< 2.5 ml). Non-HSCT Group - Pediatric Oncology Patients * Diagnosis of pediatric oncology between January 2005 and December 2020; * No HSCT performed before the onset of pubertal development (testicular volume \< 4 ml bilaterally, uterine volume \< 2.5 ml) during the same period. For Both Groups * Received prepubertal chemotherapy including at least one of the following agents: cyclophosphamide, ifosfamide, procarbazine, cisplatin, carboplatin, melphalan, thiotepa, busulfan, treosulfan; * Spontaneous pubertal development with autonomous progression, without the need for exogenous hormone therapy (testosterone or estradiol); * Endocrinological follow-up to assess growth progression conducted until the end of pubertal development at the Endocrine-Metabolic Diseases Program, UOC Pediatrics, IRCCS AOUBo; * Obtain Informed consent. Exclusion Criteria: * Delayed puberty (testicular volume \< 4 ml at age \> 14 years or Tanner stage 2 breast development at age \> 13 years) requiring exogenous hormone therapy with testosterone or estradiol; * For pediatric oncology patients not undergoing prepubertal HSCT, having received HSCT during pubertal development.